• Hepatocellular carcinoma statistics in South Korea

• Chon Young-Eun

• Jeong Soung-Won, Jun Dae-Won

• Clinical and Molecular Hepatology   2021  Volume.27  No.3 512 ~ 514

• The major diagnostic role of autoantibodies in the diagnosis of autoimmune hepatitis, a disease of a...

• Beenet Linda

• Clinical and Molecular Hepatology   2021  Volume.27  No.3 510 ~ 511

• Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with c...

• Liang Lilian Yan

• Lee Hye-Won, Wong Vincent Wai-Sun, Yip Terry Cheuk-Fung, Tse Yee-Kit, Hui Vicki Wing-Ki, Lui Gr...

• Clinical and Molecular Hepatology   2021  Volume.27  No.3 499 ~ 509

• Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Result...

• Ting Yi-Wen

• Kong Amanda Shen-Yee, Zain Shamsul Mohd, Chan Wah-Kheong, Tan Hwa-Li, Pung Yuh-Fen, Mohamed Zah...

• Clinical and Molecular Hepatology   2021  Volume.27  No.3 486 ~ 498

• The impact of unrestricted access to direct-acting antiviral among incarcerated hepatitis C virus-in...

• Wong Yu Jun

• Thurairajah Prem Harichander, Kumar Rahul, Fock Kwong Ming, Law Ngai Moh, Chong Sin-Yoong, Mane...

• Clinical and Molecular Hepatology   2021  Volume.27  No.3 474 ~ 485

• Serum milk fat globule-EGF factor 8 protein as a potential biomarker for metabolic syndrome

• Lee Han-Ah

• Lim Ji-Hwan, Joo Hyung-Joon, Lee Young-Sun, Jung Young-Kul, Kim Ji-Hoon, An Hyung-Gin, Yim...

• Clinical and Molecular Hepatology   2021  Volume.27  No.3 463 ~ 473

• Outcomes after liver transplantation in Korea: Incidence and risk factors from Korean transplantatio...

• Kim Jong-Man

• Kim Deok-Gie, Kim Ji-Hyun, Lee Keun-Sung, Lee Kwang-Woong, Ryu Je-Ho, Kim Bong-Wan, Choi D...

• Clinical and Molecular Hepatology   2021  Volume.27  No.3 451 ~ 462

• Risk of hepatocellular carcinoma in untreated patients with chronic hepatitis B: Independent of HBeA...

• Chun Ho-Soo

• Lee Min-Jong

• Clinical and Molecular Hepatology   2021  Volume.27  No.3 448 ~ 450

• An analysis of polygenic risk scores for non-alcoholic fatty liver disease

• Jun Dae-Won

• Clinical and Molecular Hepatology   2021  Volume.27  No.3 446 ~ 447

• Changes in the epidemiology and management of bacterial infections in cirrhosis

• Piano Salvatore

• Tonon Marta, Angeli Paolo

• Clinical and Molecular Hepatology   2021  Volume.27  No.3 437 ~ 445

• ¥â-blockers in advanced cirrhosis: More friend than enemy

• Yoon Ki-Tae

• Liu Hongqun, Lee Samuel S.

• Clinical and Molecular Hepatology   2021  Volume.27  No.3 425 ~ 436

• Anti-fibrotic treatments for chronic liver diseases: The present and the future

• Odagiri Naoshi

• Matsubara Tsutomu, Sato-Matsubara Misako, Fujii Hideki, Enomoto Masaru, Kawada Norifumi

• Clinical and Molecular Hepatology   2021  Volume.27  No.3 413 ~ 424

• Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the preventi...

• Lee Sung-Won

• Choi Jong-Gi, Kim Seung-Up, Lim Young-Suk

• Clinical and Molecular Hepatology   2021  Volume.27  No.3 402 ~ 412

• KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease

• Kang Seong-Hee

• Lee Hye-Won, Yoo Jeong-Ju, Cho Yu-Ri, Kim Seung-Up, Lee Tae-Hee, Jang Byoung-Kuk, Kim Sang...

• Clinical and Molecular Hepatology   2021  Volume.27  No.3 363 ~ 401